Program

Below the program for the International Workshop on NASH Biomarkers is published.

Download the final program as PDF:

NASH Biomarkers - final program

Friday 5 May 2017 - Day 1

8:00 AMRegistration & walk-in Coffee
  Session 1: Priorities in Biomarker Development for NASH
  
Chairs: Veronica Miller & Arun Sanyal
9:00 AMWorkshop Opening
9:10 AMOpening Lecture:
A pathologist, a radiologist and a hepatologist walked into a bar
Brent Tetri, MD
Saint Louis University Health Sciences Center, St. Louis, MO USA
9:40 AMInnovation in histological assessment of NASH
Pierre Bedossa, MD, PhD
University of Paris-Diderot, Paris, France
10:00 AMPanel discussion
Many perspectives, one goal
Panel members:

Pierre Bedossa, MD, PhD - University of Paris-Diderot
Brent Tetri, MD - Saint Louis University Health Sciences Center
David Kleiner MD, PhD - Center for Cancer Research, National Cancer Institute 
Sophie Megnien, MD - Genfit 
Raj Vuppalanchi, MBBS - Indiana University School of Medicine

 
11:00 AMCoffee break
 
  Session 2: Pathways to Biomarker Qualification and Acceptance
  
Chair: Chris Leptak
11:30 AMView from the Top - Potential impact of 21st Century Cures Act?
Peter Stein, MD
FDA Center for Drug Evaluation and Research, Silver Spring, MD
12:00 PMEU Perspective
Elmer Schabel, MD
European Medicines Agency, London, UK
BfArM, Bonn, Germany
12:15 PMDiscussion
12:30 PMCollaboration in action: BEST
Chris Leptak, MD, PhD
FDA Center for Drug Evaluation and Research, Silver Spring, MD
12:40 PMCollaboration in action: FNIH
Roberto Calle, MD, FACE, FACP

Foundation for the National Institutes of Health (FNIH), Bethesda, MD, USA
12:50 PMCollaboration in action: IMI
Quentin Anstee, BSc, MBBS, PhD, MRCP(UK), FRCP

Newcastle University, Newcastle, United Kingdom

1:00 PMPanel Discussion
Building synergy across the Atlantic
 
1:30 PMLunch break
2:15 PMPoster Tour 1
 
  Session 3: Circulating biomarkers
 
 Chairs: Sudha Shankar & Brent Tetri
3:00 PMLipidomics and Proteomics
Puneet Puri, MD
Virginia Commonwealth University, Richmond, VA, USA
3:20 PMRole of Genetic assessments
Quentin Anstee, BSc, MBBS, PhD, MRCP(UK), FRCP
Newcastle University, Newcastle, United Kingdom
3:40 PMCirculating nucleic acids and combination panels
Sven Francque MD, PhD
Antwerp University Hospital, Antwerp, Belgium
4:00 PMDiscussion
 
4:30 PMCoffee break
 
  Session 4: Imaging Biomarkers
  Chairs: Chris Leptak & Lara Dimick-Santos
5:00 PMMRI; what can it deliver
Claude Sirlin, MD
UC San Diego, San Diego, CA, USA
5:20 PMTransient elastography & other techniques
Raj Vuppalanchi, MBBS
Indiana University School of Medicine, Indianapolis, IN, USA
5:40 PMOral abstract presentations
6:00 PMPanel Discussion
Panel members:
Daniel Krainak, PhDFDA Office of In Vitro Diagnostics and Radiological Health
Claude Sirlin, MDUC San Diego
Raj Vuppalanchi, MBBSIndiana University School of Medicine
  
6:30 PMOpen Poster Session/Welcome Reception
7:00 PMWorkshop Dinner
 

Saturday 6 May 2017 - Day 2

 
  Session 5: Quantative assessment of hepatic health
 
 Chairs: Roberto Calle & Puneet Puri
8:00 AMBreath tests
M. Shadab Siddiqui, MD, FACP
Virginia Commonwealth University, Richmond, VA, USA
8:15 AMPrinciples of kinetic measures
Greg Everson, MD, FACP
University of Colorado Denver, Denver, CO, USA
8:30 AMOral abstract presentations
9:20 AMPanel discussion
Learning from functional, imaging and circulating biomarkers: Challenges of qualification in absence of highly effective therapy

Panel members:
Greg Everson, MD, FACP - University of Colorado Denver
Shadab Siddiqui, MD, FACP - Virginia Commonwealth University
Irene Tebbs, PhD - FDA Office of In Vitro Diagnostics and Radiological Health
Chris Leptak, MD, PhD - FDA Office for New Drugs
Eric Lefebvre, MD - Allergan
 
10:00 AMCoffee break
 
  Session 6: Challenges Opportunities in integrating 'OMICS
  Chairs: tbc
10:30 AMBig Data vs. the individual liver from a regulatory perspective
Robert Schuck, PharmD, PhD
FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA
10:45 AMBig Data vs. the individual liver from a developer's perspective
José María Mato de la Paz, PhD
CIC BioGUNE, Derio, Spain
11:00 AMFuture scenarios of algorithm building
Tom Travison, PhD
Harvard Medical School & Hebrew SeniorLife Institute for Aging Research, Boston, MA, USA
11:15 AMOral abstract presentations
11:45 AMPanel Discussion
 
12:15 PMLunch break
 
  Session 7: The Liver in Context
 
Chairs: Veronica Miller & Arun Sanyal
1:15 PMIntegrated Assessment of diabetes, cardiovascular and liver risks and its potential application in the clinical management of NAFLD
Arun Sanyal, MD, MBBS
Virginia Commonwealth University, Richmond, VA, USA
1:55 PMNavigating NASH biomarkers: From discovery to clinical practice
John Sninsky, PhD
CareDx, Brisbane, CA, USA
 
2:15 PMRound table discussion: 
The way forward

Panel members:
Malina Arazy, MD - Exalenz Bioscience
Claude Cohen-Bacrie, PhD - SuperSonic Imagine
Elizabeth Fagan, MS, MD - Perspectum Diagnostics
Céline Fournier, PhD - Echosens
Rémi Hanf, PhD - Genfit
Pablo Ortiz, MD, PhD - OWL Metabolomics
Steve Williams, MD, PhD - Somalogic
3:00 PMClosure of the workshop
 
3:00 PMEnd of workshop